Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKinsey
McKesson
Express Scripts
AstraZeneca
Medtronic

Last Updated: August 14, 2022

Investigational Drug Information for Demcizumab


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the development status for investigational drug Demcizumab?

Demcizumab is an investigational drug.

There have been 6 clinical trials for Demcizumab. The most recent clinical trial was a Phase 2 trial, which was initiated on February 1st 2015.

The most common disease conditions in clinical trials are Pancreatic Neoplasms, Lung Neoplasms, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are OncoMed Pharmaceuticals, Inc., Celgene Corporation, and Novotech (Australia) Pty Limited.

There are three US patents protecting this investigational drug and fifty-two international patents.

Recent Clinical Trials for Demcizumab
TitleSponsorPhase
A Phase 1b Study of Demcizumab Plus Pembrolizumab in Locally Advanced or Metastatic Solid TumorsCelgene CorporationPhase 1
A Phase 1b Study of Demcizumab Plus Pembrolizumab in Locally Advanced or Metastatic Solid TumorsOncoMed Pharmaceuticals, Inc.Phase 1
Study of Gemcitabine, Abraxane® Plus Placebo Versus Gemcitabine, Abraxane® Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal AdenocarcinomaCelgene CorporationPhase 2

See all Demcizumab clinical trials

Clinical Trial Summary for Demcizumab

Top disease conditions for Demcizumab
Top clinical trial sponsors for Demcizumab

See all Demcizumab clinical trials

US Patents for Demcizumab

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Demcizumab See Plans and Pricing Binding-triggered transcriptional switches and methods of use thereof The Regents of the University of California (Oakland, CA) See Plans and Pricing
Demcizumab See Plans and Pricing Cell culture medium LA JOLLA BIOLOGICS, INC. (San Diego, CA) See Plans and Pricing
Demcizumab See Plans and Pricing Meditopes and meditope-binding antibodies and uses thereof City of Hope (Duarte, CA) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Demcizumab

Drugname Country Document Number Estimated Expiration Related US Patent
Demcizumab Australia AU2011312106 2030-10-08 See Plans and Pricing
Demcizumab Australia AU2012321301 2030-10-08 See Plans and Pricing
Demcizumab Australia AU2017203871 2030-10-08 See Plans and Pricing
Demcizumab Australia AU2019283789 2030-10-08 See Plans and Pricing
Demcizumab Australia AU2021215122 2030-10-08 See Plans and Pricing
Demcizumab Canada CA2814040 2030-10-08 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKinsey
McKesson
Express Scripts
AstraZeneca
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.